Enveric Biosciences (ENVB) Competitors $1.15 -0.07 (-5.74%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.18 +0.04 (+3.04%) As of 08/1/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENVB vs. ABP, BCDA, GOVX, ALVR, IBIO, PHIO, AIMD, BTAI, CYCN, and ATNFShould you be buying Enveric Biosciences stock or one of its competitors? The main competitors of Enveric Biosciences include Abpro (ABP), BioCardia (BCDA), GeoVax Labs (GOVX), AlloVir (ALVR), iBio (IBIO), Phio Pharmaceuticals (PHIO), Ainos (AIMD), BioXcel Therapeutics (BTAI), Cyclerion Therapeutics (CYCN), and 180 Life Sciences (ATNF). These companies are all part of the "pharmaceutical products" industry. Enveric Biosciences vs. Its Competitors Abpro BioCardia GeoVax Labs AlloVir iBio Phio Pharmaceuticals Ainos BioXcel Therapeutics Cyclerion Therapeutics 180 Life Sciences Abpro (NASDAQ:ABP) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends. Does the media favor ABP or ENVB? In the previous week, Abpro's average media sentiment score of 0.00 equaled Enveric Biosciences'average media sentiment score. Company Overall Sentiment Abpro Neutral Enveric Biosciences Neutral Do institutionals & insiders hold more shares of ABP or ENVB? 23.3% of Abpro shares are held by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are held by institutional investors. 20.8% of Abpro shares are held by company insiders. Comparatively, 1.1% of Enveric Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk & volatility, ABP or ENVB? Abpro has a beta of 0.03, indicating that its stock price is 97% less volatile than the S&P 500. Comparatively, Enveric Biosciences has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Do analysts rate ABP or ENVB? Abpro currently has a consensus target price of $4.00, suggesting a potential upside of 1,579.97%. Enveric Biosciences has a consensus target price of $10.00, suggesting a potential upside of 769.57%. Given Abpro's higher possible upside, analysts clearly believe Abpro is more favorable than Enveric Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Enveric Biosciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ABP or ENVB more profitable? Abpro's return on equity of 0.00% beat Enveric Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets AbproN/A N/A -198.95% Enveric Biosciences N/A -250.28%-195.57% Which has better valuation and earnings, ABP or ENVB? Abpro has higher revenue and earnings than Enveric Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbpro$180K80.41-$7.23MN/AN/AEnveric BiosciencesN/AN/A-$9.57M-$38.38-0.03 SummaryAbpro beats Enveric Biosciences on 6 of the 8 factors compared between the two stocks. Get Enveric Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ENVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENVB vs. The Competition Export to ExcelMetricEnveric BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.84M$3.01B$5.52B$9.37BDividend YieldN/A2.44%4.74%4.12%P/E Ratio-0.0317.6228.8823.80Price / SalesN/A309.96440.8796.33Price / CashN/A41.6335.0756.59Price / Book0.498.488.255.54Net Income-$9.57M-$55.06M$3.25B$259.97M7 Day Performance-12.21%-3.99%-3.75%-4.67%1 Month Performance-8.37%8.53%2.99%3.28%1 Year Performance-86.55%6.51%25.35%17.92% Enveric Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENVBEnveric Biosciences2.6942 of 5 stars$1.15-5.7%$10.00+769.6%-86.5%$2.84MN/A-0.0320ABPAbproN/A$0.23+11.4%$4.00+1,660.6%N/A$12.40M$180K0.0015Gap DownHigh Trading VolumeBCDABioCardia2.9015 of 5 stars$2.34+4.9%$25.00+968.4%-29.0%$12.27M$60K-1.0040Negative NewsShort Interest ↑GOVXGeoVax Labs2.4524 of 5 stars$0.82+7.2%$8.88+982.3%-62.3%$12.18M$3.95M-0.2210News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionALVRAlloVirN/A$2.39-1.2%N/A-84.8%$12.05MN/A-0.12110Upcoming EarningsHigh Trading VolumeIBIOiBio1.3125 of 5 stars$0.73-0.6%$5.00+588.0%-66.5%$12.00M$375K0.00100News CoveragePHIOPhio Pharmaceuticals2.5424 of 5 stars$2.39-2.4%$14.00+485.8%-20.2%$11.76MN/A-0.3710AIMDAinos0.8833 of 5 stars$2.64-4.7%N/A-23.0%$11.61M$20K-0.4140Upcoming EarningsAnalyst UpgradeHigh Trading VolumeBTAIBioXcel Therapeutics3.6001 of 5 stars$1.89-1.0%$42.60+2,154.0%-91.4%$11.57M$2.27M-0.1490News CoverageUpcoming EarningsCYCNCyclerion TherapeuticsN/A$3.37-4.8%N/A-33.7%$11.36M$2M-2.9130Upcoming EarningsATNF180 Life Sciences0.6122 of 5 stars$2.81+49.5%N/A+89.3%$11.35MN/A-0.197News CoverageAnalyst ForecastGap DownHigh Trading Volume Related Companies and Tools Related Companies ABP Alternatives BCDA Alternatives GOVX Alternatives ALVR Alternatives IBIO Alternatives PHIO Alternatives AIMD Alternatives BTAI Alternatives CYCN Alternatives ATNF Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENVB) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enveric Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enveric Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENVB Stock Alerts